跳至主要内容
临床试验/NCT03498014
NCT03498014撤回不适用

Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.

Centre Hospitalier Universitaire de Nīmes2 个研究点 分布在 1 个国家开始时间: 2022年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
2
主要终点
Compare presence/absence undesirable events associated to opioid between groups from predefined list

研究概览

简要总结

The investigators hypothesize that opioid prescription guided by patient pharmacogenetic profile will diminish opioid-associated undesirable effects by 50% and improve medication compliance.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient must have given their free and informed consent and signed the consent form
  • The patient must be a member or beneficiary of a health insurance plan
  • The patient is at least 18 years old
  • The patient will be available for all visits
  • Patients suffer from non-cancerous chronic pain according to HAS criteria
  • Patient not having taking opioids in previous 2 months
  • Patient indicated for prescription of opioids (oxycodone, codeine or tramadol) or patient not responding to first line treatment

排除标准

  • The subject is participating in an category I interventional study, or is in a period of exclusion determined by a previous study
  • The subject refuses to sign the consent
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship
  • The patient is pregnant or breastfeeding
  • The patient is likely to procreate and does not use an effective method of contraception (contraceptive ring, surgical contraception, implant, patch, contraceptive pill, male and female condoms, IUD)
  • There is a contra-indication for opioid use
  • Patient with an addiction risk (score ≥ 8 on ORT scale).

结局指标

主要结局

Compare presence/absence undesirable events associated to opioid between groups from predefined list

时间窗: Month 3

Presence/absence of at least one undesirable event of at least grade 3 according to list in Annex 17.5 of the protocol

Compare presence/absence undesirable events associated to opioid between groups

时间窗: Month 3

Presence/absence of at least one undesirable event of at least grade 3 according to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

次要结局

  • Compare observed medication misuse between groups(Month 3)
  • Compare benefit/risk ratio of treatment between groups(Month 3)
  • Compare quality of life between patients in each group(Month 3)
  • Qualitive comparison of medication compliance between groups(Month 3)
  • Compare patient-reported pain between groups(Month 3)
  • Compare neuropathic pain between groups(Month 3)
  • Correlation between predicted phenotype and observed metabolic ratios(Month 3)
  • Metabolic profile of patients(Month 3)
  • Correlation between saliva and plasma concentration of opioids(Month 3)
  • Compare medication compliance between groups(Month 3)
  • Compare clinical therapeutic efficacy between groups(Month 3)
  • Serum concentration of tramadol, codeine or oxycodone and their metabolites by Liquid chromatography-tandem mass spectrometry (LC-MS-MS)(Day 0)
  • Number of undesirable events associated to opioid between groups(Month 3)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验